Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, announced Thursday that it plans to spin off its biosimilar development business to streamline its operations and focus more on its core Contract Development and Manufacturing Organization (CDMO) services, Azernews reports.
The South Caucasus News - SouthCaucasusNews.com